These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

490 related articles for article (PubMed ID: 32522920)

  • 21. Hydroxychloroquine administration for Japanese lupus erythematosus in Wakayama: a pilot study.
    Ikeda T; Kanazawa N; Furukawa F
    J Dermatol; 2012 Jun; 39(6):531-5. PubMed ID: 22168306
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Experience with the use of hydroxychloroquine for the treatment of lupus erythematosus.
    Momose Y; Arai S; Eto H; Kishimoto M; Okada M
    J Dermatol; 2013 Feb; 40(2):94-7. PubMed ID: 23216212
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cumulative dose of hydroxychloroquine is associated with a decrease of resting heart rate in patients with systemic lupus erythematosus: a pilot study.
    Cairoli E; Danese N; Teliz M; Bruzzone MJ; Ferreira J; Rebella M; Cayota A
    Lupus; 2015 Oct; 24(11):1204-9. PubMed ID: 25852050
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Population Pharmacokinetics of Hydroxychloroquine in Japanese Patients With Cutaneous or Systemic Lupus Erythematosus.
    Morita S; Takahashi T; Yoshida Y; Yokota N
    Ther Drug Monit; 2016 Apr; 38(2):259-67. PubMed ID: 26587870
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Longterm Hydroxychloroquine Therapy and Low-dose Aspirin May Have an Additive Effectiveness in the Primary Prevention of Cardiovascular Events in Patients with Systemic Lupus Erythematosus.
    Fasano S; Pierro L; Pantano I; Iudici M; Valentini G
    J Rheumatol; 2017 Jul; 44(7):1032-1038. PubMed ID: 28507183
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Therapy and pharmacological properties of hydroxychloroquine and chloroquine in treatment of systemic lupus erythematosus, rheumatoid arthritis and related diseases.
    Rainsford KD; Parke AL; Clifford-Rashotte M; Kean WF
    Inflammopharmacology; 2015 Oct; 23(5):231-69. PubMed ID: 26246395
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Compliance and persistence with hydroxychloroquine in South Korean patients with systemic lupus erythematosus.
    Lee SG; Park EK; Park JH; Kweon SM; Kim YK; Kim GT
    Lupus; 2018 Apr; 27(5):753-761. PubMed ID: 29157178
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The risk of hospitalized infection in patients with systemic lupus erythematosus treated with hydroxychloroquine.
    Sakai R; Honda S; Tanaka E; Majima M; Konda N; Takada H; Harigai M
    Lupus; 2020 Nov; 29(13):1712-1718. PubMed ID: 32838624
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Discontinuation of hydroxychloroquine in older patients with systemic lupus erythematosus: a multicenter retrospective study.
    Fernandez-Ruiz R; Bornkamp N; Kim MY; Askanase A; Zezon A; Tseng CE; Belmont HM; Saxena A; Salmon JE; Lockshin M; Buyon JP; Izmirly PM
    Arthritis Res Ther; 2020 Aug; 22(1):191. PubMed ID: 32807233
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The influence of obesity on hydroxychloroquine blood levels in lupus nephritis patients.
    Pedrosa T; Kupa LVK; Pasoto SG; Aikawa NE; Borba EF; Duarte NJ; Leon EP; Silva CA; Bonfá E
    Lupus; 2021 Apr; 30(4):554-559. PubMed ID: 33402039
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical Significance of Monitoring Hydroxychloroquine Levels in Patients With Systemic Lupus Erythematosus: A Systematic Review and Meta-Analysis.
    Garg S; Unnithan R; Hansen KE; Costedoat-Chalumeau N; Bartels CM
    Arthritis Care Res (Hoboken); 2021 May; 73(5):707-716. PubMed ID: 32004406
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Flares after hydroxychloroquine reduction or discontinuation: results from the Systemic Lupus International Collaborating Clinics (SLICC) inception cohort.
    Almeida-Brasil CC; Hanly JG; Urowitz M; Clarke AE; Ruiz-Irastorza G; Gordon C; Ramsey-Goldman R; Petri M; Ginzler EM; Wallace DJ; Bae SC; Romero-Diaz J; Dooley MA; Peschken C; Isenberg D; Rahman A; Manzi S; Jacobsen S; Lim S; van Vollenhoven RF; Nived O; Jönsen A; Kamen DL; Aranow C; Sanchez-Guerrero J; Gladman DD; Fortin PR; Alarcón GS; Merrill JT; Kalunian K; Ramos-Casals M; Steinsson K; Zoma A; Askanase A; Khamashta MA; Bruce IN; Inanc M; Abrahamowicz M; Bernatsky S
    Ann Rheum Dis; 2022 Mar; 81(3):370-378. PubMed ID: 34911705
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A cross-sectional study of hydroxychloroquine concentrations and effects in people with systemic lupus erythematosus.
    Carmichael SJ; Day RO; Tett SE
    Intern Med J; 2013 May; 43(5):547-53. PubMed ID: 23425382
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Health status and concomitant prescription of immunosuppressants are risk factors for hydroxychloroquine non-adherence in systemic lupus patients with prolonged inactive disease.
    Iudici M; Pantano I; Fasano S; Pierro L; Charlier B; Pingeon M; Dal Piaz F; Filippelli A; Izzo V
    Lupus; 2018 Feb; 27(2):265-272. PubMed ID: 28659047
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Systemic lupus Erythematosus activity and Hydroxychloroquine use before and after end-stage renal disease.
    Salgado Guerrero M; Londono Jimenez A; Dobrowolski C; Mowrey WB; Goilav B; Wang S; Broder A
    BMC Nephrol; 2020 Oct; 21(1):450. PubMed ID: 33115441
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The presumable effects of hydroxychloroquine and its metabolites in the treatment of systemic lupus erythematosus.
    Pan M; Jin R; Dai Y; Gao B; Liu Y; Peng X; Qiao J; Shuai Z
    Int Immunopharmacol; 2024 Jan; 126():111269. PubMed ID: 38006753
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Combined mepacrine-hydroxychloroquine treatment in patients with systemic lupus erythematosus and refractory cutaneous and articular activity.
    Ugarte A; Porta S; Ríos R; Martinez-Zapico A; Ortego-Centeno N; Agesta N; Ruiz-Irastorza G
    Lupus; 2018 Sep; 27(10):1718-1722. PubMed ID: 29635998
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Hydroxychloroquine prophylaxis for preeclampsia, hypertension and prematurity in pregnant patients with systemic lupus erythematosus: A meta-analysis.
    Duan J; Ma D; Wen X; Guo Q; Gao J; Zhang G; Xu K; Zhang L
    Lupus; 2021 Jun; 30(7):1163-1174. PubMed ID: 33853420
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Initial hydroxychloroquine monotherapy in systemic lupus erythematosus: report of three cases.
    Ichikawa K; Kirino Y; Kunishita Y; Kishimoto D; Takase-Minegishi K; Yoshimi R; Nakajima H
    Mod Rheumatol Case Rep; 2021 Jul; 5(2):259-264. PubMed ID: 33533686
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Hydroxychloroquine Dose and Hospitalizations for Active Lupus.
    Nestor J; Choi H; Mancini C; Zhou B; Zhang Y; Costenbader KH; Jorge A
    Arthritis Rheumatol; 2024 Oct; 76(10):1512-1517. PubMed ID: 38831643
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 25.